With biosimilars to AstraZeneca’s blockbuster rare blood disease med Soliris recently available in the U.S., nonprofit health plan EmblemHealth is taking a shot at the company and its alleged patent ...
Alexion Pharmaceuticals has announced that one of its international subsidiaries has initiated a voluntary recall for the remaining vials of a single lot of Soliris (exulizumab), a drug intended to ...
A board investigation found executives at Alexion Pharmaceuticals inappropriately encouraged staff to pressure customers into ordering its drug Soliris earlier than necessary to boost sales, reports ...
Alexion Pharmaceuticals agreed to pay $13 million to settle allegations that it used charities to pay kickbacks to Medicare patients, according to a STAT news report. The settlement, disclosed in a ...
Apellis Pharmaceuticals (APLS) reported positive phase 3 results of pegcetacoplan (APL-2) in PNH patients. Pegcetacoplan, the company's C3 inhibitor, managed to beat Alexion Pharmaceuticals’ (ALXN) ...
July 25 (Reuters) - Alexion Pharmaceuticals Inc.'s second-quarter loss narrowed, helped by strong sales of its product, Soliris, to treat a rare blood disorder. Shares of the Cheshire, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results